cervical
No description yet: the sentence for this tag has not been written. 9 records carry it: 9 people.
Related tags
9 records
| Cancers | Other tags | ||||
|---|---|---|---|---|---|
Bradley J. Monk Gynecologic Oncologist, Florida Cancer Specialists; Professor, University of Arizona and Creighton University; Co-Director, GOG Partners Gynaecologic oncologist who co-led KEYNOTE-826, innovaTV 301 and KEYNOTE-A18, the trials that rebuilt cervical cancer treatment. | Cervical cancer, Ovarian cancer | none | ovarian, cooperative-group | ||
Domenica Lorusso Director of Gynaecological Oncology, Humanitas San Pio X and Humanitas University, Milan · IRCCS Humanitas Research Hospital Led KEYNOTE-A18, which showed adding pembrolizumab to chemoradiotherapy improves survival in locally advanced cervical cancer. | Cervical cancer, Endometrial cancer, Ovarian cancer | none | immunotherapy, italy | ||
Ignace Vergote Emeritus Professor of Gynaecologic Oncology, University Hospitals Leuven; Chair, BGOG and ENGOT · UZ Leuven / Leuven Cancer Institute Led the EORTC trial that made neoadjuvant chemotherapy acceptable in ovarian cancer and innovaTV 301, the first ADC survival win in cervical cancer. | Ovarian cancer, Cervical cancer | none | ovarian, adc, cooperative-group | ||
Krishnansu S. Tewari Gynaecologic oncologist, Chao Family Comprehensive Cancer Center, UC Irvine · Chao Family Comprehensive Cancer Center, UC Irvine California gynaecologic oncologist who led GOG 240, the trial that made bevacizumab the first targeted drug to lengthen survival in advanced cervical cancer, and EMPOWER-Cervical 1, which did the same for the PD-1 antibody cemiplimab. | Recurrent or metastatic cervical cancer, Cervical cancer | none | gynaecological, trialist | ||
Linda Mileshkin Medical Oncologist and Director of Clinical Trials, Peter MacCallum Cancer Centre · Peter MacCallum Cancer Centre Led OUTBACK, which showed adding chemotherapy after chemoradiation does not help cervical cancer, a key negative result. | Cervical cancer, Cancer of unknown primary | none | australia, cooperative-group | ||
Marie Plante Gynaecologic oncologist, CHU de Québec - Université Laval · CHU de Québec - Université Laval Quebec surgeon who pioneered fertility-sparing surgery for cervical cancer and led SHAPE, the trial that showed a simple hysterectomy is enough for low-risk early cervical cancer. | Early cervical cancer and fertility-sparing surgery, Cervical cancer | none | surgery, de-escalation, trialist | ||
Mary McCormack Consultant Clinical Oncologist, University College London Hospitals · University College London Hospitals / UCL Cancer Institute Led INTERLACE, which showed a short course of chemotherapy before chemoradiation cuts cervical cancer deaths using cheap, available drugs. | Cervical cancer | none | chemoradiotherapy, global-health | ||
Nicoletta Colombo Director of Gynaecologic Oncology, European Institute of Oncology (IEO), Milan; Professor, University of Milan-Bicocca · IEO (European Institute of Oncology) Led KEYNOTE-826, which made pembrolizumab plus chemotherapy the first-line standard for recurrent or metastatic cervical cancer. | Cervical cancer, Ovarian cancer | none | immunotherapy, guidelines | ||
Pedro T. Ramirez Chair, Department of Obstetrics and Gynecology, Houston Methodist Hospital · Houston Methodist Dr. Mary and Ron Neal Cancer Center Surgeon who led the LACC trial, which unexpectedly showed keyhole hysterectomy worsens survival in early cervical cancer. | Cervical cancer | none | surgery |